肺炎球菌疾病的部门间成本:对部分经济评估研究的系统回顾。

IF 1.5 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus
{"title":"肺炎球菌疾病的部门间成本:对部分经济评估研究的系统回顾。","authors":"Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus","doi":"10.1080/14737167.2025.2542285","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs.</p><p><strong>Methods: </strong>Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed.</p><p><strong>Results: </strong>Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients' age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported.</p><p><strong>Conclusions: </strong>Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies.</p><p><strong>Registration: </strong>PROSPERO (CRD42023417042).</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1195-1210"},"PeriodicalIF":1.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies.\",\"authors\":\"Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus\",\"doi\":\"10.1080/14737167.2025.2542285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs.</p><p><strong>Methods: </strong>Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed.</p><p><strong>Results: </strong>Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients' age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported.</p><p><strong>Conclusions: </strong>Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies.</p><p><strong>Registration: </strong>PROSPERO (CRD42023417042).</p>\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":\" \",\"pages\":\"1195-1210\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2025.2542285\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2542285","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

本系统综述探讨了与不同年龄组肺炎球菌疾病相关的部门间成本及其对社会成本的相关影响。方法:检索四个数据库(1990-2023),从社会角度对肺炎球菌疾病进行部分经济评价。已查明的部门间费用以说明和表格形式提出。对研究的质量进行评价,并遵循PRISMA指南。结果:纳入了24项研究,分析类型差异很大。部门间成本包括五个部门:患者/家属、有偿劳动力、机会成本、教育和公共/社会服务。在纳入的研究中,主要考虑的是有偿劳动力,其次是患者/家庭。费用承担者因患者年龄组而异。每名儿童的平均年医疗费用从182美元到82,217美元不等,患者/家庭费用从240美元到846美元不等,生产力成本从654美元到25,721美元不等。在成年人中,平均每年的医疗成本为168美元至43,676美元,生产力成本为23美元至33,149美元。结论:与肺炎球菌疾病相关的部门间成本差异很大,并出现在几个部门。特别是在发展中国家,需要从更广泛的角度进行更多的疾病成本研究,以了解肺炎球菌疾病的真正经济成本,并支持为决定治疗/预防战略提供信息的努力。注册:普洛斯彼罗(CRD42023417042)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies.

Introduction: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs.

Methods: Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed.

Results: Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients' age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported.

Conclusions: Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies.

Registration: PROSPERO (CRD42023417042).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Review of Pharmacoeconomics & Outcomes Research
Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
CiteScore
4.00
自引率
4.30%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信